Loading…

LivaNova PlcLIVNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of implantable neuromodulation devices for epilepsy and heart-lung support systems used in cardiac surgery.

Momentum leader 92
Mkt cap
$5.21B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$73.0M
20-day average traded
Fwd P/E
20.9×
forward earnings
ROIC−WACC
+6.1 pp
WACC 9.4%
Hurdle
+6 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$94.54
1D+2.9%
1W+3.9%
1M+18.6%
3M+20.9%
6M+28.3%
YTD+53.6%
1Y+76.2%
ATR %3.6%
Beta1.07
52w lowhigh4.9% off high

What LivaNova does

Maker of implantable neuromodulation devices for epilepsy and heart-lung support systems used in cardiac surgery.

Implanted vagus-nerve stimulators earn on the initial surgery and again on battery replacement, so the base of patients is a recurring source of sales. Heart-lung machines are sold to hospitals along with the disposable parts used in every operation. The company is working to extend its stimulator to depression, which would widen its market.

Products and services

  • Vagus nerve stimulation (epilepsy)
  • Cardiopulmonary/heart-lung bypass systems
  • Legacy heart valve products

Customers

  • Neurologists/epilepsy centers
  • Cardiac surgery centers

Where it sits in the supply chain

  • Medical devices
  • Neuromodulation & cardiac surgery…
  • Implantable devices plus surgical…

What could go right

  • Epilepsy device adoption growth
  • Cardiac surgery volume recovery

What could go wrong

  • Product liability/regulatory risk
  • Reimbursement pressure

Moat: narrow (regulatory licence, switching costs, installed base). FDA-approved implantable neuromodulation platform with long device-replacement cycles and surgeon training lock-in.

Headquarters: London, United Kingdom · Founded: 2015 · Employees: 3,300

Named competitors

LivaNova at a glance

Size LivaNova (LIVN) is a United States Health Care company (Medical Specialties) with a market value of $5.21B, the 1149th largest of 3,085 United States companies the cockpit tracks. Shares closed at $94.54 on 18 Nov 2026.

Performance Over six months the shares gained 28.3%, against +24.2% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 11.7% over the last twelve months (peer median +3.5%); the operating margin is 15.1% (peer median 15.1%).

Valuation It trades at 20.9× forward earnings against a peer median of 20.0× (8th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.1 points above its cost of capital (9.4% WACC).

Credit LivaNova has 1 bond outstanding ($345M).

Short interest Short interest is 11.6% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026LIVN 128Peer median 126
Six months, rebased to 100: LivaNova against the median of its 20 peers (local-currency closes).

LivaNova financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.51B$1.39B$1.25B$1.15B$1.02B
Revenue growth—+11%+9%+13%—
Gross profit$1.03B$944M$872M$785M$718M
EBITDA$294M$285M$217M$160M$180M
Net income$196M-$242M$63.2M$17.5M-$86.2M
Free cash flow$129M$173M$136M$39.9M$43.4M
Capital expenditure$109M$81.0M$47.1M$35.0M$26.5M
Total debt$357M$434M$677M$640M$580M

Quarterly statements and history in the cockpit →

LivaNova competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%MMSIHAE300677DIAMMEDSHCGRAL688617ICUISTVN002223TFXLNTHCOHCTECFIECDNA0024327747LIVN6-month return →1-month return →
Up and to the right = strong over both horizons. LivaNova is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×MMSIHAE300677DIAMMEDSHC688617ICUISTVNTFXLNTHCOHCTECYPSNFIECDNA0024327747LIVNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. LivaNova is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%MMSIHAE300677DIASHC688617ICUI002223TFXLNTHCOHCTECFIE0024327747LIVNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. LivaNova is the large dot.

LivaNova competitors and peer comparison

Head to head with its named competitors (LIVN vs MDT vs BSX vs 4543.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
LivaNova LIVN$5.21B+28%+12%15%20.9×14.2%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%
Getinge GETI-B.ST$7.45B+40%-4%14%21.1×5.0%

How LivaNova compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LivaNova against its 20 peers (data as of 18 Nov 2026)
MeasureLIVNPeer medianRank in peer set
1-month return+18.6%+8.6%3rd highest of 21
6-month return+28.3%+24.2%9th highest of 21
Distance from 52-week high-4.9%-10.3%6th highest of 21
Revenue growth (TTM)+11.7%+3.5%8th highest of 21
Operating margin15.1%15.1%11th highest of 21
Forward P/E20.9×20.0×8th most expensive of 20
Growth the price implies (Req g, 7 yrs)14.2%11.8%7th most demanding of 17
Growth delivered (Del g)+8.2%+9.1%8th lowest of 17
Hurdle (Req g minus delivered)+5.9 pp+1.8 pp6th most demanding of 17
ROIC minus cost of capital+6.1 pp+2.5 pp6th highest of 21
EV / EBITDA17.0×14.8×7th most expensive of 15
Net debt / EBITDA-0.7×1.1×3rd least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%

LivaNova bonds and credit

LivaNova has 1 bond outstanding with $345M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are LivaNova's main competitors?
Named competitors: Medtronic (MDT), Boston Scientific (BSX), Terumo Corp (4543.T), Getinge AB (GETI-B.ST). The cockpit's measured peer set (industry) also includes Merit Medical Systems (MMSI), Haemonetics (HAE), Intco Medical Technology (300677.SZ), DiaSorin (DIA.MI), MiniMed (MMED), Sotera Health (SHC).
Is LivaNova expensive compared with its peers?
On forward p/e it trades at 20.9× against a peer median of 20.0×, 8th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has LivaNova stock performed?
Over six months to 18 Nov 2026 the shares returned +28.3% against +24.2% for the median peer; over one year +76.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.